Effect of hypertonic saline on mucociliary clearance and clinical outcomes in chronic bronchitis.
Journal
ERJ open research
ISSN: 2312-0541
Titre abrégé: ERJ Open Res
Pays: England
ID NLM: 101671641
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
12
05
2020
accepted:
18
05
2020
entrez:
18
8
2020
pubmed:
18
8
2020
medline:
18
8
2020
Statut:
epublish
Résumé
Mucus dehydration and impaired mucus clearance are common features of cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). In CF, inhaled hypertonic saline (HS) improves lung function and produces sustained increases in mucociliary clearance (MCC). We hypothesised that administration of HS (7% NaCl) twice daily for 2 weeks would improve clinical outcomes and produce sustained increases in MCC in COPD subjects with a chronic bronchitis (CB) phenotype. Twenty-two CB subjects completed a double-blinded, crossover study comparing inhaled HS to a hypotonic control solution (0.12% saline) administered HS was safe and well tolerated but overall produced no significant improvements in spirometry or patient-reported outcomes. CB subjects had slower baseline MCC than healthy subjects. The MCC rates over 60 min (Ave60Clr) in CB subjects following 2 weeks of HS were not different from 0.12% saline but were slower than baseline (Ave60Clr was 9.1±6.3% at baseline Inhaled HS appeared to be safe in a general CB population. A specific phenotypic subgroup may benefit from HS but requires additional study.
Sections du résumé
BACKGROUND
BACKGROUND
Mucus dehydration and impaired mucus clearance are common features of cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). In CF, inhaled hypertonic saline (HS) improves lung function and produces sustained increases in mucociliary clearance (MCC). We hypothesised that administration of HS (7% NaCl) twice daily for 2 weeks would improve clinical outcomes and produce sustained increases in MCC in COPD subjects with a chronic bronchitis (CB) phenotype.
METHODS
METHODS
Twenty-two CB subjects completed a double-blinded, crossover study comparing inhaled HS to a hypotonic control solution (0.12% saline) administered
RESULTS
RESULTS
HS was safe and well tolerated but overall produced no significant improvements in spirometry or patient-reported outcomes. CB subjects had slower baseline MCC than healthy subjects. The MCC rates over 60 min (Ave60Clr) in CB subjects following 2 weeks of HS were not different from 0.12% saline but were slower than baseline (Ave60Clr was 9.1±6.3% at baseline
CONCLUSIONS
CONCLUSIONS
Inhaled HS appeared to be safe in a general CB population. A specific phenotypic subgroup may benefit from HS but requires additional study.
Identifiants
pubmed: 32802823
doi: 10.1183/23120541.00269-2020
pii: 00269-2020
pmc: PMC7418818
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NHLBI NIH HHS
ID : P01 HL108808
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK065988
Pays : United States
Informations de copyright
Copyright ©ERS 2020.
Déclaration de conflit d'intérêts
Conflict of interest: W.D. Bennett reports grants from the NHLBI (NIH) during the conduct of the study. Conflict of interest: A.G. Henderson reports grants from National Institutes of Health during the conduct of the study. Conflict of interest: A. Ceppe reports grants from NHLBI (NIH) during the conduct of the study. Conflict of interest: K.L. Zeman reports grants from the NHLBI (NIH) during the conduct of the study. Conflict of interest: J. Wu reports grants from the NHLBI (NIH) during the conduct of the study. Conflict of interest: C. Gladman reports grants from the NHLBI (NIH), during the conduct of the study. Conflict of interest: F. Fuller reports grants from the NHLBI (NIH) during the conduct of the study. Conflict of interest: S. Gazda reports grants from the NHLBI (NIH) during the conduct of the study. Conflict of interest: B. Button reports grants from the NHLBI (NIH) during the conduct of the study. Conflict of interest: R.C. Boucher reports grants from the NHLBI (NIH) during the conduct of the study. Parion Sciences is a privately held UNC spin-out company focused on developing therapies for CF. He is chairman of the Board of Parion, has equity in it and has received monetary compensation as Board Chair. Conflict of interest: S.H. Donaldson reports grants from the NHLBI (NIH) during the conduct of the study.
Références
Int J Chron Obstruct Pulmon Dis. 2018 Jul 10;13:2113-2119
pubmed: 30022817
FASEB J. 2012 Feb;26(2):533-45
pubmed: 21990373
J Nucl Med. 1984 Apr;25(4):447-54
pubmed: 6544816
Respirology. 2017 Aug;22(6):1084-1092
pubmed: 28397992
Chest. 2007 Aug;132(2):456-63
pubmed: 17646240
Proc Am Thorac Soc. 2007 Aug 1;4(4):399-405
pubmed: 17652507
J Cyst Fibros. 2018 Sep;17(5):650-656
pubmed: 29371133
Am J Physiol Lung Cell Mol Physiol. 2011 Aug;301(2):L236-46
pubmed: 21622844
Scand J Respir Dis. 1976;57(6):281-9
pubmed: 189385
Am Rev Respir Dis. 1978 Feb;117(2):199-203
pubmed: 637404
J Pathol. 1972 Feb;106(2):81-93
pubmed: 5035319
J Aerosol Med Pulm Drug Deliv. 2013 Apr;26(2):94-100
pubmed: 23421899
Am J Respir Crit Care Med. 1995 Mar;151(3 Pt 1):630-4
pubmed: 7881648
Eur Respir J. 2004 Apr;23(4):518-22
pubmed: 15083747
Chest. 1993 May;103(5):1390-6
pubmed: 8486016
Ann Am Thorac Soc. 2014 Apr;11 Suppl 3:S154-60
pubmed: 24754824
Respir Care. 2001 Aug;46(8):798-825
pubmed: 11463370
N Engl J Med. 2011 Oct 27;365(17):1567-75
pubmed: 22029978
Am J Respir Crit Care Med. 2007 Sep 1;176(5):454-9
pubmed: 17556723
Respir Med. 2008 Nov;102(11):1545-55
pubmed: 18662868
Chest. 2018 Aug;154(2):370-377
pubmed: 29559310
COPD. 2018 Dec;15(6):572-580
pubmed: 30712400
Am J Respir Cell Mol Biol. 2010 Dec;43(6):635-40
pubmed: 20042711
COPD. 2005 Mar;2(1):75-9
pubmed: 17136966
J Aerosol Med Pulm Drug Deliv. 2010 Dec;23(6):363-9
pubmed: 20863250
Eur Respir J. 2018 May 17;51(5):
pubmed: 29599187
J Aerosol Med Pulm Drug Deliv. 2013 Jun;26(3):157-64
pubmed: 23517172
Am J Respir Crit Care Med. 2015 Jul 15;192(2):182-90
pubmed: 25909230
Eur J Respir Dis Suppl. 1985;139:93-100
pubmed: 3862617
PLoS One. 2009 Dec 16;4(12):e8157
pubmed: 20016779
N Engl J Med. 1979 Feb 22;300(8):381-5
pubmed: 759914
Am Rev Respir Dis. 1986 Aug;134(2):248-53
pubmed: 3090916
Am J Respir Crit Care Med. 2003 Jan 15;167(2):158-63
pubmed: 12411282
N Engl J Med. 2006 Jan 19;354(3):241-50
pubmed: 16421365
Scand J Respir Dis. 1973;54(5):272-81
pubmed: 4777380
Science. 2012 Aug 24;337(6097):937-41
pubmed: 22923574
Eur Respir J. 1999 Sep;14(3):678-85
pubmed: 10543292
J Appl Physiol (1985). 2015 Jun 15;118(12):1483-90
pubmed: 25911685
Am Rev Respir Dis. 1978 Feb;117(2):205-14
pubmed: 637405
N Engl J Med. 2006 Jan 19;354(3):229-40
pubmed: 16421364
Exp Lung Res. 2000 Apr-May;26(3):149-62
pubmed: 10813088
Am J Respir Crit Care Med. 2019 Oct 15;200(8):e70-e88
pubmed: 31613151